JP2005508829A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005508829A5 JP2005508829A5 JP2001585782A JP2001585782A JP2005508829A5 JP 2005508829 A5 JP2005508829 A5 JP 2005508829A5 JP 2001585782 A JP2001585782 A JP 2001585782A JP 2001585782 A JP2001585782 A JP 2001585782A JP 2005508829 A5 JP2005508829 A5 JP 2005508829A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- apoptotic
- cells
- patient
- blood cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000001640 apoptogenic effect Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 9
- 210000000601 blood cell Anatomy 0.000 description 7
- 239000003814 drug Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2309417 CA2309417A1 (en) | 2000-05-25 | 2000-05-25 | Apoptotic entities for use in treatment of endothelium dysfunction disorders |
| PCT/CA2001/000760 WO2001089538A2 (en) | 2000-05-25 | 2001-05-25 | Apoptotic entities for use in treatment of endothelium dysfunction disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005508829A JP2005508829A (ja) | 2005-04-07 |
| JP2005508829A5 true JP2005508829A5 (enExample) | 2008-07-10 |
Family
ID=4166242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001585782A Withdrawn JP2005508829A (ja) | 2000-05-25 | 2001-05-25 | 内皮機能障害の治療における使用のためのアポトーシス体 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7279156B2 (enExample) |
| EP (1) | EP1289536A2 (enExample) |
| JP (1) | JP2005508829A (enExample) |
| AU (1) | AU6198801A (enExample) |
| CA (1) | CA2309417A1 (enExample) |
| WO (1) | WO2001089538A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2309417A1 (en) * | 2000-05-25 | 2001-11-25 | Anthony E. Bolton | Apoptotic entities for use in treatment of endothelium dysfunction disorders |
| CA2309518A1 (en) * | 2000-05-25 | 2001-11-25 | Vasogen Ireland Limited | Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders |
| CA2309424A1 (en) * | 2000-05-25 | 2001-11-25 | Vasogen Ireland Limited | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders |
| US20030211548A1 (en) * | 2002-01-29 | 2003-11-13 | Oncolmmunin, Inc. | Visualization and quantitiation of cellular cytotoxicity using cell-permeable fluorogenic protease substrates and caspase activity indicator markers |
| CN110022885A (zh) * | 2016-08-19 | 2019-07-16 | 免疫疗法有限责任公司 | 气体处理输送系统和方法 |
| US20210393990A1 (en) * | 2020-06-17 | 2021-12-23 | Donald Murrill BOTTA, JR. | Ultrasound therapy for systemic immune modulation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5980954A (en) * | 1992-02-07 | 1999-11-09 | Vasogen Ireland Limited | Treatment of autoimmune diseases |
| US6696092B2 (en) * | 1992-02-07 | 2004-02-24 | Vasogen Ireland Limited | Endothelial lining effects and treatment of vasospastic disorders |
| WO1993015778A1 (en) | 1992-02-07 | 1993-08-19 | Anthony Ernest Bolton | Method of inhibiting the aggregation of blood platelets |
| NZ306395A (en) | 1995-05-05 | 2000-02-28 | Vasogen Inc | Treatment of blood to remove symptoms of vascular disorders by elevation of temperature, ultraviolet radiation or treatment with an oxidative environment |
| EP1078043A1 (en) | 1998-05-11 | 2001-02-28 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | New apoptotic bodies, monocyte derived cells containing the same, a process for their preparation and their uses as vaccines |
| AU768300B2 (en) * | 1998-11-13 | 2003-12-04 | Vasogen Ireland Limited | Method for preventing and reversing atherosclerosis in mammals |
| CA2269364A1 (en) | 1999-04-19 | 2000-10-19 | Vasogen Ireland Limited | Treatment of inflammatory and allergic disorders |
| CA2271190A1 (en) * | 1999-05-06 | 2000-11-06 | Vasogen Ireland Limited | Improved method for treating mammals with modified mammalian blood |
| CA2309417A1 (en) * | 2000-05-25 | 2001-11-25 | Anthony E. Bolton | Apoptotic entities for use in treatment of endothelium dysfunction disorders |
| US7122208B2 (en) * | 2001-04-06 | 2006-10-17 | Vasogen Ireland Limited | Compositions containing apoptotic entities |
| US7255880B2 (en) * | 2003-04-03 | 2007-08-14 | Vasogen Ireland Limited | Treatment of endothelin-related disorders |
-
2000
- 2000-05-25 CA CA 2309417 patent/CA2309417A1/en not_active Abandoned
-
2001
- 2001-05-25 US US09/866,569 patent/US7279156B2/en not_active Expired - Fee Related
- 2001-05-25 AU AU61988/01A patent/AU6198801A/en not_active Abandoned
- 2001-05-25 JP JP2001585782A patent/JP2005508829A/ja not_active Withdrawn
- 2001-05-25 WO PCT/CA2001/000760 patent/WO2001089538A2/en not_active Ceased
- 2001-05-25 EP EP20010935898 patent/EP1289536A2/en not_active Withdrawn
-
2007
- 2007-09-13 US US11/855,092 patent/US20080063631A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004522714A5 (enExample) | ||
| JP2010047609A (ja) | Ｍｃｐ−１プロテインの軽減生産に活性な薬剤組成物 | |
| FR2798065B1 (fr) | Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson | |
| JP2004509061A5 (enExample) | ||
| JP2002528502A5 (enExample) | ||
| HUP9800467A2 (hu) | Hialuronsav alkalmazása szövetközi cisztitisz kezelésére alkalmas gyógyászati készítmények előállítására | |
| JP2006522006A5 (enExample) | ||
| JP2001510795A5 (enExample) | ||
| AR016798A1 (es) | Uso de una cepa de lactobacillus para la elaboracion de un medicamento | |
| JP2015524444A5 (enExample) | ||
| JP2003534281A5 (enExample) | ||
| JP2002524415A5 (enExample) | ||
| WO2000041504A3 (en) | Use of tertbutylhydroquinone for lowering blood cholesterol and/or blood triblycerides | |
| JP2004537500A5 (enExample) | ||
| JP2002534479A5 (enExample) | ||
| JP2004519424A5 (ja) | インシュリン分泌促進剤およびＨＭＧ−Ｃｏ−Ａレダクターゼ阻害剤およびＡＣＥ阻害剤から選択される活性成分を含む組み合わせ | |
| JP2002530353A5 (enExample) | ||
| JP2003534282A5 (enExample) | ||
| Zein | Interferons in the management of viral hepatitis | |
| WO2001089537A3 (en) | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders | |
| Thijs et al. | Why is antihypertensive drug therapy needed in elderly patients with systolodiastolic hypertension? | |
| JP2003517020A5 (enExample) | ||
| JP2023554354A5 (enExample) | ||
| Baciewicz et al. | Bleeding associated with doxycycline and warfarin treatment | |
| JP2004500315A5 (enExample) |